Gland Pharma’s Hyderabad Facility Receives Establishment Inspection Report From USFDA

The company’s earnings before interest, tax, depreciation and amortisation slipped to Rs 297.06 crore, down 8%, for the July-September quarter of the current fiscal 2025 as against Rs 324.08 crore for the same quarter in the previous financial year 2024.

Margins narrowed at 21.1% for the three months ended Sept. 30, 2024, as against 23.6% for the same quarter last year.

Shares of Gland Pharma closed 0.20% higher at Rs 1,679.20 apiece on the National Stock Exchange, compared to a 0.47% fall in the benchmark Nifty. The share price has fallen 13.09% in the last 12 months.

Out of 16 analysts tracking the company, eight maintain a ‘buy’ rating on the stock, one recommends ‘hold,’ and seven suggest ‘sell,’ according to Bloomberg data. The average of 12-month analysts’ price targets implies a potential upside of 16.1%.

  • Related Posts

    • Pharma
    • February 17, 2025
    • 73 views
    GSK Pharma shares gain 20% following strong Q3FY25 results

    GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

    • Pharma
    • February 17, 2025
    • 68 views
    Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

    Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Wow! What a Change of Heart in Practitioners of Allopathy!

    Wow! What a Change of Heart in Practitioners of Allopathy!

    GSK Pharma shares gain 20% following strong Q3FY25 results

    GSK Pharma shares gain 20% following strong Q3FY25 results

    Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

    Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

    US Tariffs on pharma: What are the potential impact on Indian drugmakers

    US Tariffs on pharma: What are the potential impact on Indian drugmakers

    Twin Health bats a1000 before enters Digital Health NY 100

    Twin Health bats a1000 before enters Digital Health NY 100

    US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

    US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%